Chemomab Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-24.22	-27.65	-12.48	-5.95	-27.12	-13.8	-9.81	-4.74
Depreciation & Amortization	0.07	0.06	0.03	0.02	0.28	0.07	0.05	0.04
Share-Based Compensation	1.49	3.21	2.02	0.13	1.16	1.93	0.73	0.27
Other Operating Activities	-0.95	4.01	-1.95	0.56	9.23	-2.42	0.51	0.7
Operating Cash Flow	-23.61	-20.37	-12.37	-5.24	-16.46	-14.22	-8.52	-3.73
Capital Expenditures	-0	-0.07	0.76	-0.04	-0.1	-0.21	-0.03	-0.08
Change in Investments	15.88	19.6	-45.95	-0.02	0	0	0	0.15
Investing Cash Flow	15.88	19.53	-45.19	-0.06	-0.1	-0.21	-0.03	0.08
Share Issuance / Repurchase	3.5	-0.95	58.64	3.5	30.5	22.9	5.67	6.5
Debt Issued / Paid	0	0	0	0	0	0.02	0	0
Other Financing Activities	-	0.14	2.44	1.25	-3.88	-2.3	-0.42	-0.44
Financing Cash Flow	3.5	-0.81	61.07	4.75	26.62	20.62	5.24	6.06
Exchange Rate Effect	0	0	0	0	0	0	0.2	-0.05
Net Cash Flow	-4.23	-1.65	3.51	-0.55	10.07	6.18	-3.31	2.41
Free Cash Flow	-23.61	-20.44	-11.61	-5.28	-16.55	-14.44	-8.55	-3.81
Free Cash Flow Per Share	-2.01	-1.80	-1.12	-0.77	-38.44	-91.41	-20.82	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).